These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 25505208)

  • 61. [Lenvatinib in radioiodine refractory thyroid carcinomas].
    de la Fouchardiere C
    Bull Cancer; 2016 Nov; 103(11):905-910. PubMed ID: 27817859
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Beneficial effects of sorafenib on tumor progression, but not on radioiodine uptake, in patients with differentiated thyroid carcinoma.
    Hoftijzer H; Heemstra KA; Morreau H; Stokkel MP; Corssmit EP; Gelderblom H; Weijers K; Pereira AM; Huijberts M; Kapiteijn E; Romijn JA; Smit JW
    Eur J Endocrinol; 2009 Dec; 161(6):923-31. PubMed ID: 19773371
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Cabozantinib versus everolimus, nivolumab, axitinib, sorafenib and best supportive care: A network meta-analysis of progression-free survival and overall survival in second line treatment of advanced renal cell carcinoma.
    Amzal B; Fu S; Meng J; Lister J; Karcher H
    PLoS One; 2017; 12(9):e0184423. PubMed ID: 28886175
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Targeted therapies in advanced differentiated thyroid cancer.
    Carneiro RM; Carneiro BA; Agulnik M; Kopp PA; Giles FJ
    Cancer Treat Rev; 2015 Sep; 41(8):690-8. PubMed ID: 26105190
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Successful use of sorafenib after bortezomib failure in metastatic follicular thyroid cancer - a case report.
    Eisner F; Schaberl-Moser R; Gerger A; Samonigg H; Pichler M
    Onkologie; 2013; 36(6):368-70. PubMed ID: 23774152
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Vandetanib: a guide to its use in advanced medullary thyroid cancer.
    Keating GM; Lyseng-Williamson KA; Frampton JE
    BioDrugs; 2012 Dec; 26(6):431-5. PubMed ID: 22938056
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Sorafenib therapy decreases the clearance of thyrotropin.
    Verloop H; Smit JW; Dekkers OM
    Eur J Endocrinol; 2013 Feb; 168(2):163-7. PubMed ID: 23125304
    [TBL] [Abstract][Full Text] [Related]  

  • 68. [Systemic therapies for advanced thyroid cancer - an update].
    Brandenburg T; Machlah YM; Führer-Sakel D
    Laryngorhinootologie; 2024 Sep; 103(9):637-642. PubMed ID: 38346701
    [TBL] [Abstract][Full Text] [Related]  

  • 69. XL184 (cabozantinib) for medullary thyroid carcinoma.
    Durante C; Russo D; Verrienti A; Filetti S
    Expert Opin Investig Drugs; 2011 Mar; 20(3):407-413. PubMed ID: 21314233
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Complete disappearance of liver metastases in a patient with iodine-refractory differentiated thyroid cancer subjected to sorafenib re-challenge.
    Marotta V; Colao A; Faggiano A
    Endocrine; 2015 Dec; 50(3):824-5. PubMed ID: 25754914
    [No Abstract]   [Full Text] [Related]  

  • 71. Pazopanib, Cabozantinib, and Vandetanib in the Treatment of Progressive Medullary Thyroid Cancer with a Special Focus on the Adverse Effects on Hypertension.
    Milling RV; Grimm D; Krüger M; Grosse J; Kopp S; Bauer J; Infanger M; Wehland M
    Int J Mol Sci; 2018 Oct; 19(10):. PubMed ID: 30347815
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Response to sorafenib in a pediatric patient with papillary thyroid carcinoma with diffuse nodular pulmonary disease requiring mechanical ventilation.
    Iyer P; Mayer JL; Ewig JM
    Thyroid; 2014 Jan; 24(1):169-74. PubMed ID: 23544852
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Lenvatinib in Advanced, Radioactive Iodine-Refractory, Differentiated Thyroid Carcinoma.
    Yeung KT; Cohen EE
    Clin Cancer Res; 2015 Dec; 21(24):5420-6. PubMed ID: 26487760
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Relationship between toxicities and clinical benefits of newly approved tyrosine kinase inhibitors in thyroid cancer: A meta-analysis of literature.
    Ye X; Zhu Y; Cai J
    J Cancer Res Ther; 2015 Oct; 11 Suppl 2():C185-90. PubMed ID: 26506873
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Toxic Effects of Sorafenib in Patients With Differentiated Thyroid Carcinoma Compared With Other Cancers.
    Jean GW; Mani RM; Jaffry A; Khan SA
    JAMA Oncol; 2016 Apr; 2(4):529-34. PubMed ID: 26847808
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Use of Tyrosine Kinase Inhibitors for Treatment of Medullary Thyroid Carcinoma.
    Dadu R; Hu MN; Grubbs EG; Gagel RF
    Recent Results Cancer Res; 2015; 204():227-49. PubMed ID: 26494392
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Medullary thyroid cancer in the era of tyrosine kinase inhibitors: to treat or not to treat--and with which drug--those are the questions.
    Cabanillas ME; Hu MI; Jimenez C
    J Clin Endocrinol Metab; 2014 Dec; 99(12):4390-6. PubMed ID: 25238206
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Tyrosine kinase inhibitors in iodine-refractory differentiated thyroid cancer: experience in clinical practice.
    Molina-Vega M; García-Alemán J; Sebastián-Ochoa A; Mancha-Doblas I; Trigo-Pérez JM; Tinahones-Madueño F
    Endocrine; 2018 Feb; 59(2):395-401. PubMed ID: 29275532
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Spontaneous regression of metastatic papillary renal cell cancer after cessation of treatment with sorafenib.
    Grenader T; Rosenbaum E; Zilber S; Bogot N; Shavit L
    Clin Genitourin Cancer; 2013 Jun; 11(2):201-3. PubMed ID: 23266054
    [No Abstract]   [Full Text] [Related]  

  • 80. Response to sorafenib treatment in advanced metastatic thyroid cancer.
    Pitoia F
    Arq Bras Endocrinol Metabol; 2014 Feb; 58(1):37-41. PubMed ID: 24728162
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.